{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:47:50Z","timestamp":1782096470437,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyloidosis comprises a heterogeneous group of diseases characterized by extracellular deposition of \u03b2-pleated-sheet fibrillar proteins that cause progressive organ dysfunction. Among immunoglobulin-related amyloidosis, combined heavy- and light-chain (AHL) amyloidosis is extremely rare, which accounts for approximately 7%. Several studies have demonstrated that complement components can be detected in renal amyloidosis. We report a rare case of renal AHL amyloidosis with marked complement deposition with clinicopathologic and proteomic insights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 76-year-old woman with a five-year history of microscopic hematuria developed mild renal dysfunction (serum creatinine 1.05\u00a0mg\/dL) and proteinuria (0.95\u00a0g\/day). Physical and serologic evaluations showed no evidence of systemic amyloidosis or autoimmune disease. Serum and urine immunofixation detected an IgG-\u03ba M-protein, and bone marrow findings were consistent with monoclonal gammopathy of undetermined significance. Kidney biopsy demonstrated Congo red\u2013positive fibrillar deposits with IgG1, \u03ba, and complement (C3\/C1q) staining. Electron microscopy revealed non-branching fibrils measuring 8 to 12\u00a0nm in diameter. Because marked complement deposition was observed, fibrillary glomerulonephritis (FGN) was considered in the differential diagnosis. However, negative Dna J heat-shock protein family B member 9 immunostaining raised suspicion for amyloidosis. Mass spectrometry identified IgG1 heavy and \u03ba light chains together with serum amyloid P and apolipoprotein E, confirming IgG1-\u03ba-type AHL amyloidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case illustrates a presentation of AHL amyloidosis with marked complement deposition. Recent study reveals that complement components can be detected in a subset of amyloidosis cases. These features can complicate the differential diagnosis from FGN and highlight the importance of an integrated diagnostic approach combining histopathology, immunostaining, and proteomic analysis. Furthermore, clone-directed therapy targeting the pathogenic plasma cell clone may represent a rational therapeutic strategy for monoclonal immunoglobulin\u2013associated renal disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05017-6","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:46:24Z","timestamp":1777560384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A rare case of renal AHL amyloidosis with marked complement deposition: clinicopathologic and proteomic findings"],"prefix":"10.1186","volume":"27","author":[{"given":"Yoshihiro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shinzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Shishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arimi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"5017_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","volume":"29","author":"JN Buxbaum","year":"2022","unstructured":"Buxbaum JN, Dispenzieri A, Eisenberg DS, F\u00e4ndrich M, Merlini G, Saraiva MJM, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2022;29:213\u201319.","journal-title":"Amyloid"},{"key":"5017_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/j.ajkd.2024.01.530","volume":"84","author":"N Leung","year":"2024","unstructured":"Leung N, Nasr SH. 2024 update on classification, etiology, and typing of renal amyloidosis: a review. Am J Kidney Dis. 2024;84:361\u201373.","journal-title":"Am J Kidney Dis"},{"key":"5017_CR3","doi-asserted-by":"crossref","unstructured":"Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95:1852-64.","DOI":"10.1016\/j.mayocp.2020.06.029"},{"key":"5017_CR4","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/ndt\/gfaf042","volume":"40","author":"M Allinovi","year":"2025","unstructured":"Allinovi M, Trivioli G, Gaudio C, L\u2019Imperio V, Rauf MU, Gillmore JD. The evolving spectrum of kidney amyloidosis: advances in diagnosis, typing and treatment. Nephrol Dial Transpl. 2025;40:1826\u201337.","journal-title":"Nephrol Dial Transpl"},{"key":"5017_CR5","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3390\/diagnostics14242892","volume":"14","author":"GS Netti","year":"2024","unstructured":"Netti GS, Troise D, Rossini M, Catalano V, De Luca F, Khalid J, et al. Diagnostic and therapeutic aspects of monoclonal gammopathies of renal significance (MGRS): an update. Diagnostics (Basel). 2024;14:2892.","journal-title":"Diagnostics (Basel)"},{"key":"5017_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ki.2012.414","volume":"83","author":"SH Nasr","year":"2013","unstructured":"Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, et al. The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013;83:463\u201370.","journal-title":"Kidney Int"},{"key":"5017_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.kint.2025.04.007","volume":"108","author":"SH Nasr","year":"2025","unstructured":"Nasr SH, Royal V, Best Rocha A, B\u00fcttner-Herold M, Roufosse C, Bridoux F, et al. Renal Pathology Society\/International Kidney and Monoclonal gammopathy Research Group consensus on pathologic definitions and terminology of monoclonal gammopathy-associated kidney lesions. Kidney Int. 2025;108:184\u201393.","journal-title":"Kidney Int"},{"key":"5017_CR8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2215\/CJN.03870319","volume":"14","author":"NK Andeen","year":"2019","unstructured":"Andeen NK, Troxell ML, Riazy M, Avasare RS, Lapasia J, Jefferson JA, et al. Fibrillary glomerulonephritis: clinicopathologic features and atypical cases from a multi-institutional cohort. Clin J Am Soc Nephrol. 2019;14:1741\u201350.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5017_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2215\/CJN.08300910","volume":"6","author":"SH Nasr","year":"2011","unstructured":"Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, Leung N, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011;6:775\u201384.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5017_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2215\/CJN.07030712","volume":"8","author":"S Sethi","year":"2013","unstructured":"Sethi S, Theis JD, Vrana JA, Fervenza FC, Sethi A, Qian Q, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol. 2013;8:915\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5017_CR11","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1681\/ASN.2006050460","volume":"17","author":"LM Dember","year":"2006","unstructured":"Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17:3458\u201371.","journal-title":"J Am Soc Nephrol"},{"key":"5017_CR12","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.amjmed.2022.01.003","volume":"135","author":"R Gurung","year":"2022","unstructured":"Gurung R, Li T. Renal amyloidosis: Presentation, Diagnosis, and Management. Am J Med. 2022;135:S38\u201343.","journal-title":"Am J Med"},{"key":"5017_CR13","doi-asserted-by":"crossref","unstructured":"Yao Y, Wang SX, Zhang YK, Qu Z, Liu G, Zou WZ. A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. Nephrol Dial Transpl. 2013;28:689\u201397.","DOI":"10.1093\/ndt\/gfs501"},{"key":"5017_CR14","doi-asserted-by":"crossref","unstructured":"Lux A, Gottwald J, Behrens HM, Daniel C, Amann K, R\u00f6cken C. Complement 9 in amyloid deposits. Amyloid 2021;28:199\u2013208.","DOI":"10.1080\/13506129.2021.1932799"},{"key":"5017_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/13506129.2025.2467282","volume":"32","author":"MJ Rees","year":"2025","unstructured":"Rees MJ, Muchtar E, Atallah-Yunes SA, Dasari S, Leung N, Gertz M, et al. Proteomic determinants of renal organ response in light-chain amyloidosis. Amyloid. 2025;32:200\u20132.","journal-title":"Amyloid"},{"key":"5017_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.kint.2023.11.023","volume":"105","author":"C Charalampous","year":"2024","unstructured":"Charalampous C, Dasari S, McPhail E, Theis JD, Vrana JA, Dispenzieri A, et al. A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis. Kidney Int. 2024;105:484\u201395.","journal-title":"Kidney Int"},{"key":"5017_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/13506129.2017.1360272","volume":"24","author":"S Rubinstein","year":"2017","unstructured":"Rubinstein S, Cornell RF, Du L, Concepcion B, Goodman S, Harrell S, et al. Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid. 2017;24:205\u201311.","journal-title":"Amyloid"},{"key":"5017_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","volume":"15","author":"N Leung","year":"2019","unstructured":"Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D\u2019Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"5017_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/j.ajkd.2018.03.017","volume":"72","author":"MP Alexander","year":"2018","unstructured":"Alexander MP, Dasari S, Vrana JA, Riopel J, Valeri AM, Markowitz GS, et al. Congophilic fibrillary glomerulonephritis: A case series. Am J Kidney Dis. 2018;72:325\u201336.","journal-title":"Am J Kidney Dis"},{"key":"5017_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1681\/ASN.2017030306","volume":"29","author":"S Dasari","year":"2018","unstructured":"Dasari S, Alexander MP, Vrana JA, Theis JD, Mills JR, Negron V, et al. DnaJ heat shock protein family B Member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol. 2018;29:51\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"5017_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","volume":"99","author":"JA Vrana","year":"2014","unstructured":"Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014;99:1239\u201347.","journal-title":"Haematologica"},{"key":"5017_CR22","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2215\/CJN.10491012","volume":"8","author":"SM Said","year":"2013","unstructured":"Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8:1515\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5017_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ekir.2023.10.005","volume":"9","author":"NK Andeen","year":"2023","unstructured":"Andeen NK, DiFranza L, Kung VL, Henriksen K, Gupta R, Dinesh K, et al. AA amyloidosis with Ig-Dominant Staining and Diagnostically Unusual Features. Kidney Int Rep. 2023;9:162\u201370.","journal-title":"Kidney Int Rep"},{"key":"5017_CR24","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325\u201332.","journal-title":"Blood"},{"key":"5017_CR25","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957\u20139.","journal-title":"Blood"},{"key":"5017_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ki.2012.108","volume":"82","author":"S Sethi","year":"2012","unstructured":"Sethi S, Vrana JA, Theis JD, Leung N, Sethi A, Nasr SH, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012;82:226\u201334.","journal-title":"Kidney Int"},{"key":"5017_CR27","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.kint.2024.02.013","volume":"105","author":"B Madden","year":"2024","unstructured":"Madden B, Singh RD, Haas M, Palma LMP, Sharma A, Vargas MJ, et al. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy. Kidney Int. 2024;105:1077\u201387.","journal-title":"Kidney Int"},{"key":"5017_CR28","doi-asserted-by":"publisher","first-page":"e2406192121","DOI":"10.1073\/pnas.2406192121","volume":"121","author":"N Frischauf","year":"2024","unstructured":"Frischauf N, Strasser J, Borg EGF, Labrijn AF, Beurskens FJ, Preiner J. Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding. Proc Natl Acad Sci U S A. 2024;121:e2406192121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5017_CR29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"G Palladini","year":"2021","unstructured":"Palladini G, Kastritis E, Maurer MS, Zonder JA, Minnema MC, Wechalekar AD, et al. Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone for AL amyloidosis. N Engl J Med. 2021;385:46\u201358.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05017-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:15:16Z","timestamp":1782094516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05017-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5017"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05017-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8722969\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Shizuoka General Hospital, Japan (approval No. SGHIRB#2025047CR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient and her family. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}